Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, Roszik J, Meric-Bernstam F, Subbiah V.
Dembla V, et al. Among authors: subbiah v.
Sci Rep. 2017 Nov 21;7(1):15963. doi: 10.1038/s41598-017-13114-8.
Sci Rep. 2017.
PMID: 29162825
Free PMC article.